SULF2 methylation is prognostic for lung cancer survival and increases sensitivity to topoisomerase-I inhibitors via induction of ISG15.

Oncogene · 2012 · PMC3307938 · PMID 22158045

Europe PMC DOI

hedged sentences

0.2700

closest p · 5.4× alpha

0.2700

boldest claim

The sentences

did not reach statistical significancep = 0.27not close (p > 0.1)

Although the median progression free survival (PFS) of 7.8 months for SULF2M (95% CI, 6.6 – 10.7) was slightly better than 7.2 months seen for SULF2U patients (95% CI, 5.1 – 11.4), it did not reach statistical significance (logrank test, p = 0.27; and HR = 0.77, 0.48 –1.23).

also in 111,027 other papers

marginally significantno p-value reported

While OS was marginally significant, more SULF2M patients (38.3%, 95% CI, 26.6 – 55.1%) survived beyond two years compared to SULF2U patients (19.4%, 95% CI, 9.4 – 39.7%; Figure 2 ).

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.